 |
Professor Mark Cooper giving CCS's
2017 public lecture. See video
|
Congratulations to
Professor Mark Cooper, Head of Central Clinical School's Department of Diabetes, on his successful grant award from
Diabetes Australia Research Program (DARP)! The grant of $60,000 is for one year, to investigate the mechanisms underlying the action of lowering glucose in type 2 diabetes (T2D) in a particular class of drugs known as Glucagon-like peptide-1 (GLP-1) receptor agonists.
These type of drugs improve cardiovascular (heart) and renal (kidney) outcomes, but it's not clear how or why given that there are no GLP-1 receptors in these organs. Prof Cooper is planning to test his hypothesis that specific hormone activity within cells is causing the protective effects.
No comments:
Post a Comment
Thankyou for your comment. We moderate all messages and may take a little time to review your comment. Please email inquiries to ccs.comms@monash.edu.